Avalo Therapeutics Inc(AVTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -4.74 | Insider Own | 10.39% | Shs Outstand | 52.9M | Perf Week | 3.46% |
| Market Cap | 0.38B | Forward P/E | - | EPS next Y | 0.16% | Insider Trans | -6.39% | Shs Float | 48.1M | Perf Month | -52.04% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -0.59 | Inst Own | 128.38% | Short Float | 24.89% | Perf Quarter | -60.28% |
| Income | -0.10B | P/S | 6408.83 | EPS this Y | 50.17% | Inst Trans | 118.27% | Short Ratio | 7.91 | Perf Half Y | -47.7% |
| Sales | 0.00B | P/B | 0.85 | EPS next 5Y | 19.36% | ROA | -32.5% | Short Interest | 11.96M | Perf YTD | -60.52% |
| Book/sh | 8.48 | P/C | 0.96 | EPS past 3/5Y | 82.35% 70.2% | ROE | -36.27% | 52W High | -70.46% ($24.27) | Perf Year | -60.24% |
| Cash/sh | 7.46 | P/FCF | - | Sales past 3/5Y | -85.16% -61.19% | ROIC | -22.26% | 52W Low | 9.8% ($6.53) | Perf 3Y | -67.81% |
| Dividend Est. | $0.01 (0.16%) | EV/EBITDA | - | EPS Y/Y TTM | 14.74% | Gross Margin | -84.75% | Volatility(W/M) | 7.07% 8.74% | Perf 5Y | -99.89% |
| Dividend TTM | - | EV/Sales | -225.84 | Sales Y/Y TTM | -86.62% | Oper. Margin | -154844.07% | ATR (14) | 0.99 | Perf 10Y | -99.94% |
| Dividend Ex-Date | - | Quick Ratio | 19.31 | EPS Q/Q | 56.51% | Profit Margin | -170055.93% | RSI (14) | 22.62 | Recom | 1.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 19.31 | Sales Q/Q | - | SMA20 | -33.32% ($10.75) | Beta | 0.68 | Target Price | $36 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/6 | SMA50 | -51.45% ($14.77) | Rel Volume | 1.01 | Prev Close | $7.44 |
| Employees | 33 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -42.44% - | SMA200 | -55.28% ($16.03) | Avg Volume(3M) | 1.51M | Price | $7.17 |
| IPO | 2015/11/13 | Option/Short | Yes/Yes | Trades | 11802 | Volume | 1,534,548 | Change | -3.63% |
🧬 Avalo Therapeutics, ticker AVTX, is a clinical-stage biotech company developing novel antibody therapeutics that target immune-mediated inflammatory diseases. Centered on its lead asset abdakibart (development code AVTX-009), a monoclonal antibody targeting interleukin-1 beta, the company is building a pipeline aimed at chronic inflammatory indications such as hidradenitis suppurativa. With no product revenue of its own, it represents a typical clinical-stage biotech structure in which corporate value is driven by clinical progress and capital raises.
Over the past 1 year, on the lower side
70% below its 1-year high.
Traded about as much as usual. That is 101% of its average volume.
AVTX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +50.2% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $640,883. Peers typically go for $1,268.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.9%. The S&P 500 did +65% over the same period.
Tap to view numbers
The dividend is on the small side
Pays 0.16% annually in dividends.
Tap to view numbers
Short interest is a burden
24.9% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #241 of 597 in the industry
Based on market cap of $385M.
ZURA#239 Zura Bio Ltd $389M PER - 
TECX#240 Tectonic Therapeutic Inc $387M PER - AVTX#241 Avalo Therapeutics Inc $385M PER - 
RZLT#242 Rezolute Inc $382M PER - 
RLMD#243 Relmada Therapeutics Inc $382M PER - 
FAQ
What kind of company is AVTX?
AVTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AVTX?
The market cap of AVTX is approximately $385M, ranking 3,364 within its sector.
Does AVTX pay dividends?
AVTX has a dividend yield of approximately 0.16%, with an annual dividend of $0.01.
What is the 52-week high and low for AVTX?
AVTX has recorded a 52-week high of $24.27 and a low of $6.53.
